Stevanato Group/$STVN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Stevanato Group
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
- Ticker
- $STVN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 6,010
- Headquarters
- Piombino Dese, Italy
- Website
- www.stevanatogroup.com
Stevanato Group Metrics
BasicAdvanced
$5.4B
36.00
$0.55
0.75
$0.06
0.31%
Price and volume
Market cap
$5.4B
Beta
0.75
52-week high
$27.00
52-week low
$12.89
Average daily volume
349K
Dividend rate
$0.06
Financial strength
Current ratio
1.613
Quick ratio
1.077
Long term debt to equity
0.206
Total debt to equity
0.288
Dividend payout ratio (TTM)
10.95%
Interest coverage (TTM)
16.13%
Profitability
EBITDA (TTM)
336.693
Gross margin (TTM)
29.42%
Net profit margin (TTM)
10.99%
Operating margin (TTM)
17.84%
Effective tax rate (TTM)
29.98%
Revenue per employee (TTM)
$223,800
Management effectiveness
Return on assets (TTM)
5.45%
Return on equity (TTM)
9.13%
Valuation
Price to earnings (TTM)
36.002
Price to revenue (TTM)
3.931
Price to book
3.48
Price to tangible book (TTM)
3.69
Price to free cash flow (TTM)
-157.115
Free cash flow yield (TTM)
-0.64%
Free cash flow per share (TTM)
-0.126
Dividend yield (TTM)
0.31%
Forward dividend yield
0.31%
Growth
Revenue change (TTM)
7.00%
Earnings per share change (TTM)
0.17%
3-year revenue growth (CAGR)
5.93%
3-year earnings per share growth (CAGR)
-4.11%
What the Analysts think about Stevanato Group
Analyst ratings (Buy, Hold, Sell) for Stevanato Group stock.
Analyst projections of the future price of Stevanato Group stock.
Bulls say / Bears say
Second-quarter revenue rose 8%, while high-value solutions grew 16% and reached 45% of sales; adjusted EBITDA margin expanded to 26%. Stevanato lifted its full-year adjusted EBITDA outlook, suggesting the richer product mix is already supporting growth and profitability. (Stevanato Group)
Management reported robust EZ-fill cartridge demand and said 2027 capacity was fully covered, with new production capacity due to come onstream in early 2027. More sales of these higher-value products could support the mix shift and improve returns as capacity scales. (Stock Analysis)
A customer’s Alina pen-injector platform received regulatory approval in several European countries, providing a concrete step towards commercial adoption of Stevanato’s drug-delivery products. This could help the company sell integrated device-and-container solutions rather than relying only on packaging. (Stevanato Group)
Capital spending is weighing on cash generation: second-quarter free cash flow was negative €32 million and net debt stood at €360.3 million. Fishers is not expected to be fully ramped until late 2028, so the new capacity may take time to earn an adequate return. (Stevanato Group, Stock Analysis)
The Engineering segment remains a drag: second-quarter revenue fell 2%, and the company expects a mid-single-digit to low-double-digit decline for the full year. Management also cautioned that sales cycles are longer, making a sustained recovery less certain. (Stevanato Group)
GLP-1 products represented about 22%-23% of company revenue, and management said customer inventory was moving from prior stockpiling towards normalisation. That concentration leaves growth exposed if packaging orders do not keep pace with patient uptake. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Stevanato Group Financial Performance
Revenues and expenses
Stevanato Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
Stevanato Group News
AllArticlesVideos
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
Business Wire2 hours ago
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Business Wire1 week ago
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
Business Wire2 weeks ago
Funds containing Stevanato Group
Fund name | Fund size | $STVN weighting |
|---|---|---|
Invesco Dow Jones Islamic Global Developed Markets$IGDA | $1.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.